Table 2.

PPI exposure and pancreatic cancer risk

	Cases/Controls N= (4113/16072)	Crude OR (95%CI)	adjusted1 OR (95% CI)
Never users	1801/11,576
Former users	137/279	3.54 (2.83–4.43)	3.36 (2.67–4.22)
Short-term, active users	1109/705	10.50 (9.36–11.79)	10.42 (9.26–11.73)
Intermediate-term, active users	243/629	2.54 (2.16–3.00)	2.47 (2.09–2.92)
Long-term, active users	823/2883	1.94 (1.75–2.14)	1.85 (1.67–2.06)

N=, number of individuals; OR, odds ratio; 95% CI, 95% confidence interval;

¹Adjusted for: diabetes, smoking, alcohol use and obesity

Stratification:

1. former users: most recent PPI prescription >6 months prior to index date
2. active users: most recent PPI prescription < 6 months prior to index date

   1. short-term, active users: first prescription <12 months before the index date
   2. intermediate-term, active users: first prescription 12 –24 months before the index date
   3. long-term, active users: first prescription >24 months before index date